Abelacimab: First Factor XI Inhibitor to Enroll Patients in a Phase 3 Clinical Trial
/PRNewswire/ -- Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today...
Source: prnewswire.com